Previous studies have shown that higher levels of ex vivo IgG responses to tumor‐associated antigens were related to shorter recurrence‐free survival (RFS) in breast cancer, whereas IgA levels were not significantly associated with RFS.56 This evidence concerns the gene CD79A and neoplasm.